ArticleBMC infectious diseases2025
Evaluation of an antibiotic stewardship program for promoting rational antibiotic use in an ICU in China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges in Antimicrobial Treatment and Antimicrobial Stewardship in Hospital-Acquired Infections in Adult Burn Patients.European burn journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe irrational use of broad-spectrum antibiotics in intensive care units (ICUs) has led to increasing bacterial resistance in recent years. However, research on the effectiveness of antimicrobial stewardship programs (ASPs) in Chinese ICUs is limited. This study aimed to assess the impact of ASP implementation on antibiotic use and bacterial resistance in a Chinese ICU.
methodsThis retrospective, interventional study employed an interrupted time series design and was conducted in an ICU beginning on June 1, 2019. The ASP included the formation of a multidisciplinary team, the development of facility-specific criteria, prescriber education, the implementation of preauthorization processes, and retrospective prescription audit and feedback (RPAF). Patient data were collected from June 1, 2018, to May 31, 2020. An interrupted time series analysis was used to evaluate the impact of the ASP.
resultsA total of 862 patients were admitted during the pre-intervention period, and 946 patients were admitted during the post-intervention period. The interrupted time series analysis demonstrated a reduction in the monthly consumption of carbapenems (β3: -2.25 DDD/100 PD, p < 0.001) and linezolid (β3: -0.49 DDD/100 PD, p = 0.003) after the intervention. Additionally, a decrease in the incidence of bacteremia caused by multidrug-resistant (MDR) organisms overall (β3:-0.03 events/100 PD, p = 0.036) and MDR Gram-positive organisms (β3:-0.01 events/100 PD, p = 0.002) was observed post-intervention.
conclusionReduced antimicrobial consumption and decreased incidence of infections associated with MDR organisms were observed following the implementation of an ASP strategy that incorporated clinical pharmacists as core team members. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.